[go: up one dir, main page]

NO20060101L - Forsterkning av oligodendrocyttdifferensiering - Google Patents

Forsterkning av oligodendrocyttdifferensiering

Info

Publication number
NO20060101L
NO20060101L NO20060101A NO20060101A NO20060101L NO 20060101 L NO20060101 L NO 20060101L NO 20060101 A NO20060101 A NO 20060101A NO 20060101 A NO20060101 A NO 20060101A NO 20060101 L NO20060101 L NO 20060101L
Authority
NO
Norway
Prior art keywords
reinforcement
oligodendrocyte differentiation
field
neurodegenerative diseases
diseases
Prior art date
Application number
NO20060101A
Other languages
English (en)
Inventor
Michel Revel
Judith Chebat
Peter Lonai
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL15643003A external-priority patent/IL156430A0/xx
Priority claimed from IL15922603A external-priority patent/IL159226A0/xx
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO20060101L publication Critical patent/NO20060101L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/32—Polylysine, polyornithine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Den foreliggende oppfinnelse er generelt i området nevrologiske sykdommer og lidelser, særlig i feltet nevrodegenerative sykdommer hvori myelinskjeden på nervene blir tapt. IL6R/IL6-kimærer blir brukt til å fremme dannelsen av oligodendrocytter fra embryone stamceller for behandling av nevrodegenerative sykdommer eller posttraumatisk nerveskade.
NO20060101A 2003-06-12 2006-01-06 Forsterkning av oligodendrocyttdifferensiering NO20060101L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL15643003A IL156430A0 (en) 2003-06-12 2003-06-12 Enhancement of oligodendrocyte differentiation
IL15922603A IL159226A0 (en) 2003-12-07 2003-12-07 Enhancement of oligodendrocyte differentiation
PCT/IL2004/000507 WO2004111210A1 (en) 2003-06-12 2004-06-13 Enhancement of oligodendrocyte differentiation

Publications (1)

Publication Number Publication Date
NO20060101L true NO20060101L (no) 2006-01-06

Family

ID=33554211

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060101A NO20060101L (no) 2003-06-12 2006-01-06 Forsterkning av oligodendrocyttdifferensiering

Country Status (8)

Country Link
US (1) US8617887B2 (no)
EP (1) EP1631662A1 (no)
JP (1) JP4878553B2 (no)
AU (2) AU2004247961B2 (no)
CA (1) CA2527847C (no)
IL (1) IL172352A (no)
NO (1) NO20060101L (no)
WO (1) WO2004111210A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2597611A1 (en) * 2005-02-11 2006-08-17 Elan Pharmaceuticals, Inc. Methods of identifying genes which modulate myelination
AU2012261726B2 (en) * 2005-08-29 2015-03-12 Technion Research & Development Foundation Ltd. Media for Culturing Stem Cells
US8476070B2 (en) 2005-08-29 2013-07-02 Technion Research & Development Foundation Limited Media for culturing stem cells
GB0613756D0 (en) * 2006-07-12 2006-08-23 Univ Sheffield Cell culture medium
ES2874223T3 (es) 2006-08-02 2021-11-04 Technion Res & Dev Foundation Métodos de expansión de células madre embrionarias en un cultivo en suspensión
AU2012293276B2 (en) * 2011-08-07 2016-07-14 Kadimastem Ltd. Method of identifying agents that affect maturation, survival and myelination
EP2674482A1 (en) * 2012-06-15 2013-12-18 Merck Patent GmbH Process for producing cell culture media
CN112912495A (zh) * 2018-09-14 2021-06-04 学校法人庆应义塾 星形胶质细胞的制造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331406B1 (en) * 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
DE19756864C5 (de) * 1997-12-19 2014-07-10 Oliver Brüstle Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten
US6238922B1 (en) * 1999-02-26 2001-05-29 Stemcells, Inc. Use of collagenase in the preparation of neural stem cell cultures
IL130586A0 (en) * 1999-06-21 2000-06-01 Yeda Res & Dev IL6RIL6 chimera for the treatment of demyelinating diseases
AU6319901A (en) * 2000-05-17 2001-11-26 Geron Corp Neural progenitor cell populations
EP1317273B1 (en) * 2000-09-14 2006-05-03 Ares Trading S.A. Use of il-6r/il-6 chimera in huntington's disease
AU2002307455A1 (en) * 2001-04-20 2002-11-05 Memorial Sloan-Kettering Cancer Center Generation of differentiated tissue from nuclear transfer embryonic stem cells and methods of use
IL147412A0 (en) * 2001-12-31 2002-08-14 Yeda Res & Dev The use of il6r/il6 chimera in nerve cell regeneration

Also Published As

Publication number Publication date
EP1631662A1 (en) 2006-03-08
US8617887B2 (en) 2013-12-31
CA2527847A1 (en) 2004-12-23
AU2010202311A1 (en) 2010-06-24
AU2004247961A1 (en) 2004-12-23
AU2010202311B2 (en) 2013-08-22
CA2527847C (en) 2015-09-29
JP4878553B2 (ja) 2012-02-15
AU2004247961B2 (en) 2010-06-24
IL172352A0 (en) 2011-08-01
US20070237748A1 (en) 2007-10-11
IL172352A (en) 2015-10-29
WO2004111210A1 (en) 2004-12-23
JP2006526997A (ja) 2006-11-30

Similar Documents

Publication Publication Date Title
WO2008057459A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
EP2275095A3 (en) Neurogenesis by muscarinic receptor modulation
WO2002010768A3 (en) Model for alzheimer's disease and other neurodegenerative diseases
WO2004076639A3 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2007022506A3 (en) Methods and compositions for treating neurological disease
EP2453024A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
ATE252078T1 (de) Carbonsäuren und carbonsäureisostere von n- heterocyclischen verbindungen
WO2002000913A3 (en) MODULATION OF β-AMYLOID LEVELS BY β-SECRETASE BACE2
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
WO2008157791A3 (en) Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones
EP1546179A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF POLO-SIMILAR KINASE
NO20084488L (no) Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
NO20006078L (no) N-bundete sulfen-amider av N-heterocykliske karboksylsyrer eller karboksylsyre-isostere
WO2008129023A3 (en) Oligonucleotide compositions for the treatment of alzheimer's disease
NO20060101L (no) Forsterkning av oligodendrocyttdifferensiering
WO2005004814A3 (en) Sirt1 and genetic disorders
Osinalde et al. Impaired proteostasis in rare neurological diseases
DE60134430D1 (de) Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe
DE60137414D1 (de) Zusammensetzungen zur stimulierung der regeneration und der wiederherstellung des nervensystems durch regulierung der arginase 1- und polyamin-synthese
EA200601607A1 (ru) Сульфонамидные соединения для лечения нейродегенеративных расстройств
WO2005061002A3 (en) Composition and methods for modulating cns activity
NO20052153L (no) Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden